Avalyn Pharma Inc
AVLNHealthcare|Biotechnology|USA
$28.05
-0.94 (-3.24%)
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06951217 An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | P2 | Recruiting | 340 | Open-label | — |
| NCT07194382 AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | Idiopathic Pulmonary Fibrosis (IPF) | P2 | Recruiting | 160 | RCT, Double-blind | AP02, Placebo |
| NCT06329401 A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | P2 | Active | 375 | RCT, Double-blind | AP01 |